Studies using rat CKD (nephritic and 5/6 nephrectomy) models showed that monoclonal-FGF23 antibody injection was associated with a reversal of secondary hyperparathyroidism, increase in serum vitamin D and Ca2+ and normalization of bone markers [118,119]. This evidence concerns the gene FGF23 and chronic kidney disease.